The Siemens Biograph mCT systems are combined X-Ray Computed Tomography (CT) and Positron Emission Tomography (PET) scanners that provide registration and fusion of high resolution physiologic and anatomic information.

The CT component produces cross-sectional images of the body by computer reconstruction of X-Ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles. The PET subsystem images and measures the distribution of PET radiopharmaceuticals in humans for the purpose of determining various metabolic (molecular) and physiologic functions within the human body and utilizes the CT for fast attenuation correction maps for PET studies and precise anatomical reference for the fused PET and CT images.

The system maintains independent functionality of the CT and PET devices, allowing for single modality CT and / or PET diagnostic imaging.

These systems are intended to be utilized by appropriately trained health care professionals to aid in detecting, localizing, diagnosing, staging of lesions, tumors, disease and organ function for the evaluation of diseases and disorders such as, but not limited to, cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.

Device Description

The Biograph mCT systems are combined multi-slice X-Ray Computed Tomography and Positron Emission Tomography scanners. These systems are designed for whole body oncology, neurology and cardiology examinations. The Biograph mCT systems provide registration and fusion of high-resolution metabolic and anatomic information from the two major components of each system (PET and CT). Additional components of the system include a patient handling system and acquisition and processing workstations with associated software.

Biograph mCT software is a command based program used for patient management, data management, scan control, image reconstruction and image archival and evaluation. All images conform to DICOM imaging format requirements.

The software for the Biograph mCT systems which is the subject of this application is substantially equivalent to the commercially available Biograph mCT software. Modifications include:

Additional configuration license options
Improvement of performance characteristics of the PET and CT, and
Optimization of workflows

AI/ML Overview

This 510(k) premarket notification describes modifications to the Siemens Biograph mCT systems. It primarily focuses on demonstrating substantial equivalence to a previously cleared device (K081453) rather than presenting a performance study with acceptance criteria for a new device's clinical efficacy regarding a specific diagnostic task.

Therefore, the document does not contain the detailed information required to fill out a table of acceptance criteria and reported device performance related to a specific diagnostic task or a clinical study proving new performance claims. The modifications are described as:

Additional configuration license options
Improvement of performance characteristics of the PET and CT
Optimization of workflows

These are technical modifications and workflow improvements, not changes that require a new clinical trial to establish diagnostic performance against specific metrics like sensitivity or specificity for a disease. The safety and effectiveness section refers to risk management and compliance with industry standards, not a clinical performance study.

Based on the provided text, here's what can be extracted and what cannot:

1. Table of Acceptance Criteria and the Reported Device Performance:

Acceptance Criteria: Not specified in terms of clinical diagnostic performance (e.g., sensitivity, specificity, accuracy for detecting a specific condition). The notification focuses on technical equivalence and compliance with safety standards (e.g., ISO 14971, IEC 60601-1, 21 CFR 1020.30, 21 CFR 1020.33).
Reported Device Performance: No specific performance metrics (like accuracy, sensitivity, specificity, or lesion detection rates) are reported in the context of a new study proving these modifications meet specific clinical acceptance criteria. The document states "Improvement of performance characteristics of the PET and CT," but does not quantify these improvements or link them to clinical acceptance criteria.

2. Sample size used for the test set and the data provenance (e.g., country of origin of the data, retrospective or prospective):

Not Applicable. The document does not describe a clinical performance study with a test set of patient data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

Not Applicable. No clinical performance study is described.

4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:

Not Applicable. No clinical performance study is described.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

Not Applicable. This is a clearance for modifications to a PET/CT scanner, not an AI-assisted diagnostic device, and no MRMC study is described.

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

Not Applicable. Not an algorithm-only device in the context of a new diagnostic claim.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):

Not Applicable. No clinical performance study is described.

8. The sample size for the training set:

Not Applicable. No machine learning or AI model training is described for new diagnostic claims. The "improvements" are likely engineering changes and software optimizations, not AI model updates.

9. How the ground truth for the training set was established:

Not Applicable. No machine learning or AI model training is described.

Summary of Document Focus:

This 510(k) is for modifications to an existing device (Biograph mCT systems) to demonstrate substantial equivalence to a previously cleared predicate device (K081453). The modifications primarily relate to:

Technical/System Improvements: "Improvement of performance characteristics of the PET and CT" and "Optimization of workflows."
Software Enhancements: "Additional configuration license options."

The safety and effectiveness section refers to compliance with risk management (ISO 14971) and electrical/radiation safety standards (IEC 60601-1 series, 21 CFR 1020.30, 21 CFR 1020.33), which are typical for hardware and software modifications in imaging devices. It does not outline new clinical performance studies to prove quantitative improvements in diagnostic accuracy for specific conditions. The "Indications for Use" remain broad, covering general diagnostic purposes of PET/CT.

Summary

{0}------------------------------------------------

Siemens Biograph mCT Modifications 510(k) Premarket Notification_________________________________________________________________________________________________________________________________________________

ーー

. 、こ

-l

ー

s required by 21 CFR Part 807.87(h)

3 2010 SEP

K161550

ldentification of the Submitter

Submitter:	M. Alaine Medio, RACPET and PCS Regulatory Projects ManagerSiemens Medical Solutions USA, Inc.Molecular Imaging810 Innovation DriveKnoxville, TN 37932
Telephone Number:	(865)218-2703
Fax Number:	(865)218-3019
Date of Submission:	June 3, 2010
Identification of the product
Device Proprietary Name:	Biograph mCT-X and mCT-S Systems
Common Name:	Positron Emission Tomography (PET) SystemComputed Tomography (CT) System
Classification Name:	Emission Computed Tomography System per 21 CFR892.1200Computed Tomography X-Ray System per 21 CFR892.1750
Product Code:	90 KPS and 90 JAK
Classification Panel:	Radiology
Device Class:	Class II
Marketed Devices to which Equivalence is claimed
Device	Manufacturer	510(k) Number
Biograph mCT-X andmCT-S (Biograph HD)	Siemens Medical Solutions USA, Inc	K081453

・

{1}------------------------------------------------

Device Description:

The software for the Biograph mCT systems which is the subject of this application is substantially equivalent to the commercially available Biograph mCT software. Modifications include:

Additional configuration license options t
Improvement of performance characteristics of the PET and CT, and .
. Optimization of workflows

Safety and Effectiveness:

The device labeling contains instructions for use and any necessary cautions and warnings to provide for safe and effective use of the device.

Risk Management is ensured via a risk analysis in compliance with ISO 14971:2007 to identify and provide mitigation to potential hazards beginning early in the design cycle and continuing throughout the development of the product. Siemens Medical Solutions, USA Inc. adheres to recognized and established industry standards such as IEC 60601-1 series and 21 CFR 1020.30 and 21 CFR 1020.33 to minimize electrical, mechanical and radiation hazards.

Indications for Use:

The system-maintains independent functionality of the GF and PET devices, allowing for single modality CT and / or PET diagnostic imaging.

{2}------------------------------------------------

Siemens Biograph mCT Modifications 510(k) Premarket Notification

cardiovascular disease, neurological disorders and cancer. The images produced by the system can also be used by the physician to aid in radiotherapy treatment planning and interventional radiology procedures.

. . . . . . . . .

Page 26 of 3386

{3}------------------------------------------------

Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three bars representing the department's mission. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the eagle.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room - WO66-G609 Silver Spring, MD 20993-0002

Ms. Alaine Medio, RAC PET and PCS Regulatory Projects Manager Siemens Medical Solutions USA, Inc. 810 Innovation Drive KNOXVILLE TN 37932

SEP 3 2010

Re: K101550

Trade/Device Name: Biograph mCT Family - mCT-X and mCT-S Regulation Number: 21 CFR 892.1200 Regulation Name: Emission computed tomography system Regulatory Class: II Product Code: KPS and JAK Dated: June 3, 2010 Received: June 4. 2010

Dear Ms. Medio:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

{4}------------------------------------------------

medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tolli the (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Donald J. St.Pierre Acting Director Division of Radiological Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for USE

510(k) Number (if known):

K 101550 SEP : 8 2010

Device Name: Biograph mCT Family - mCT·X and mCT·S

Indications for Use:

The CT component produces cross-sectional images of the body by computer reconstruction of X-Ray transmission data from either the same axial plane taken at different angles or spiral planes taken at different angles. The PET subsystem images and measures the distribution of PET radiopharmaceuticals in humans for the purpose.of determining various metabolic (molecular) and physiologic functions within the human body and utilizes the CT for fast attenuation correction maps for PET studies and precise anatomical reference for the fused PET and CT images.

The system maintains independent functionality of the CT and PET devices, allowing for single modality CT and I or PET diagnostic imaging.

Prescription Use______________________________________________________________________________________________________________________________________________________________ (Part 21 CFR 801 Subpart D) AND/OR

Over the Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

DSL

Page 1 of __

510K/101556

Regulation Number and Section

§ 892.1200 Emission computed tomography system.

(a)
Identification. An emission computed tomography system is a device intended to detect the location and distribution of gamma ray- and positron-emitting radionuclides in the body and produce cross-sectional images through computer reconstruction of the data. This generic type of device may include signal analysis and display equipment, patient and equipment supports, radionuclide anatomical markers, component parts, and accessories.(b)
Classification. Class II.